Paul Tudor Jones’s TherapeuticsMD TXMD Stock Holding History

Paul Tudor Jones’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,980	Closed	-$200K	–	1951
2021 Q1	$200K	Buy	+2,980	New	+$233K	﹤0.01%	1433
2020 Q1	–	Sell	-1,462	Closed	-$177K	–	1341
2019 Q4	$177K	Buy	+1,462	New	+$210K	0.01%	1004
2018 Q1	–	Sell	-899	Closed	-$271K	–	1250
2017 Q4	$271K	Sell	899 -4,760	-84%	-$1.33M	0.01%	856
2017 Q3	$1.5M	Buy	+5,659	New	+$1.64M	0.04%	276
2016 Q2	–	Sell	-462	Closed	-$148K	–	1939
2016 Q1	$148K	Sell	462 -445	-49%	-$152K	﹤0.01%	1562
2015 Q4	$470K	Buy	907 +308	+51%	+$114K	0.01%	925
2015 Q3	$175K	Buy	599 +199	+50%	+$70.7K	0.01%	1365
2015 Q2	$157K	Buy	+400	New	+$141K	﹤0.01%	1372

Other funds holding TXMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Paul Tudor Jones's TXMD Position: Q2 2021 in Review

Paul Tudor Jones sold out of TherapeuticsMD (TXMD) in Q2 2021, closing a stake of 2,980 shares — an estimated $200K sold.

Paul Tudor Jones first reported a position in TXMD in Q2 2015 and held it in 8 quarters. The position peaked at $1.5M in Q3 2017. 154 funds tracked by Wall St. Rank hold TXMD as of Q2 2021.

Paul Tudor Jones reported no remaining TherapeuticsMD position as of Q2 2021 after selling out during the quarter.
Paul Tudor Jones sold 2,980 TherapeuticsMD shares in Q2 2021, an estimated $200K.
Paul Tudor Jones first reported a position in TherapeuticsMD in Q2 2015 and held it in 8 quarters.
Paul Tudor Jones's TherapeuticsMD position peaked at $1.5M in Q3 2017.
154 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2021.

Based on Tudor Investment Corp's 13F filing for Q2 2021, filed 16 Aug 2021.